Compare FedEx Corporation (FDX) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FedEx Corporation vs Eli Lilly And Co — how do they compare? FedEx Corporation trades at $316.87 (market cap $74.78B), while Eli Lilly And Co trades at $1,176.53 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 13.8× FedEx Corporation's market cap, and FedEx Corporation pays the higher dividend (1.56%). Which is the better fit depends on your goals.
| FDX | LLY | |
|---|---|---|
Market Cap | $74.78B | $1.03T |
Sector | Industrials | Health |
52-Week High | $338.75 | $1.24K |
52-Week Low | $174.81 | $625.65 |
Enterprise Value | $104.42B | $1.07T |
Dividend Yield | 1.56% | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FedEx (FDX) trades at $313.66, down slightly by 0.03% on the day, with a bearish technical signal from moving averages and ADX indicators. The company reported revenue of $87.93B for 2025, with a net income margin of 4.68%, and has beaten EPS estimates in recent quarters. Recent corporate actions include a dividend payment and a $1.4B sale of its supply chain unit to CMA CGM, aimed at streamlining operations.
The outlook for FDX is mixed; analyst consensus is bullish with a $360.27 price target, but technicals and margin pressures pose risks. Investment opportunities lie in cost-cutting initiatives and steady revenue growth, while risks include competitive threats from Amazon and soft shipping demand. The stock's valuation appears reasonable with a P/E of 16.9.
LLY trades at $1,154.27, down 2.6% today, amid a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q1 2026 EPS of $8.55 surpassing the $6.97 forecast. Revenue surged to $65.18B in 2025, driving a net income margin of 34.99%. Recent news includes the acquisition of AtaiBeckley for $2.8 billion, expanding its neuroscience pipeline.
Outlook remains positive with a consensus price target of $1,380, though high valuation multiples (P/E 41.09) and competitive pressures in obesity drugs present risks. Analyst sentiment is strongly bullish (73% buy ratings), supporting further upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
